Mechanisms for SU5416 as a radiosensitizer of endothelial cells
- Authors:
- Eun Ho Kim
- Mi-Sook Kim
- Youn Kyoung Jeong
- Ilsung Cho
- Seung Hoon You
- Sung Ho Cho
- Hanna Lee
- Won-Gyun Jung
- Hag Dong Kim
- Joon Kim
-
Affiliations: Division of Heavy Ion Clinical Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Research Center for Radiotherapy, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea, Laboratory of Biochemistry, Division of Life Sciences, Korea University, Seoul 136-701, Republic of Korea - Published online on: August 21, 2015 https://doi.org/10.3892/ijo.2015.3127
- Pages: 1440-1450
This article is mentioned in:
Abstract
Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW and Hillan KJ: Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours. J Clin Pathol. 57:504–512. 2004. View Article : Google Scholar : PubMed/NCBI | |
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z and Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 300:1155–1159. 2003. View Article : Google Scholar : PubMed/NCBI | |
Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE and Abdollahi A: Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65:3643–3655. 2005. View Article : Google Scholar : PubMed/NCBI | |
Poggi MM, Coleman CN and Mitchell JB: Sensitizers and protectors of radiation and chemotherapy. Curr Probl Cancer. 25:334–411. 2001. View Article : Google Scholar : PubMed/NCBI | |
Chan LW and Camphausen K: Angiogenic tumor markers, anti-angiogenic agents and radiation therapy. Expert Rev Anticancer Ther. 3:357–366. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wachsberger P, Burd R and Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res. 9:1957–1971. 2003.PubMed/NCBI | |
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI | |
Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565–5570. 2000.PubMed/NCBI | |
Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H and Hallahan DE: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2413–2419. 2001.PubMed/NCBI | |
Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99–106. 1999.PubMed/NCBI | |
Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, et al: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15:29–41. 2000.PubMed/NCBI | |
Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G and Gajewski TF: Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 10:4048–4054. 2004. View Article : Google Scholar : PubMed/NCBI | |
Bäckman U, Svensson A and Christofferson R: Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis. 5:267–274. 2002. View Article : Google Scholar | |
Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A and Huber PE: Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. 14:2210–2219. 2008. View Article : Google Scholar : PubMed/NCBI | |
Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, et al: SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63:3755–3763. 2003.PubMed/NCBI | |
Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P and Dicker AP: Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 11:835–842. 2005.PubMed/NCBI | |
Ning S, Laird D, Cherrington JM and Knox SJ: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 157:45–51. 2002. View Article : Google Scholar : PubMed/NCBI | |
Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H and Song CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 62:1702–1706. 2002.PubMed/NCBI | |
Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, McMahon G, Choy H and Hallahan DE: Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys. 58:844–850. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zips D, Eicheler W, Geyer P, Hessel F, Dörfler A, Thames HD, Haberey M and Baumann M: Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 65:5374–5379. 2005. View Article : Google Scholar : PubMed/NCBI | |
Edwards E, Geng L, Tan J, Onishko H, Donnelly E and Hallahan DE: Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62:4671–4677. 2002.PubMed/NCBI | |
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G and Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:4009–4016. 2003.PubMed/NCBI | |
Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G and Lipson KE: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 61:3660–3668. 2001.PubMed/NCBI | |
Kumar P, Benedict R, Urzua F, Fischbach C, Mooney D and Polverini P: Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest. 85:756–767. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lea DE: Actions of Radiations on Living Cells. 2nd edition. Cambridge University Press; New York, NY: 1955 | |
Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW and Ingram AJ: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 277:12710–12717. 2002. View Article : Google Scholar : PubMed/NCBI | |
Yang J, Yu Y and Duerksen-Hughes PJ: Protein kinases and their involvement in the cellular responses to genotoxic stress. Mutat Res. 543:31–58. 2003. View Article : Google Scholar : PubMed/NCBI | |
Kabakov AE, Makarova YM and Malyutina YV: Radio-sensitization of human vascular endothelial cells through HSP90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys. 71:858–865. 2008. View Article : Google Scholar : PubMed/NCBI | |
Tan J and Hallahan DE: Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res. 63:7663–7667. 2003.PubMed/NCBI | |
Cherrington JM, Strawn LM and Shawver LK: New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res. 79:1–38. 2000. View Article : Google Scholar : PubMed/NCBI | |
Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 4:241–249. 1998.PubMed/NCBI | |
Kawaguchi T, Yamamoto S, Kudoh S, Goto K, Wakasa K and Sakurai M: Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma. Anticancer Res. 17:3743–3746. 1997. | |
Toi M, Hoshina S, Takayanagi T and Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 85:1045–1049. 1994. View Article : Google Scholar : PubMed/NCBI | |
Gasparini G and Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol. 13:765–782. 1995.PubMed/NCBI | |
Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN and Harris AL: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol. 74:762–766. 1994. View Article : Google Scholar : PubMed/NCBI | |
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI | |
Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S and Jurkiewicz MJ: Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg. 168:373–380. 1994. View Article : Google Scholar : PubMed/NCBI | |
Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med Berl. 77:527–543. 1999. View Article : Google Scholar : PubMed/NCBI | |
Boehm-Viswanathan T: Is angiogenesis inhibition the Holy Grail of cancer therapy? Curr Opin Oncol. 12:89–94. 2000. View Article : Google Scholar : PubMed/NCBI | |
Brieger J, Kattwinkel J, Berres M, Gosepath J and Mann WJ: Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep. 18:1597–1601. 2007.PubMed/NCBI | |
Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI | |
Chapman JD and Gillespie CJ: Radiation-induced events and their time-scale in mammalian cells. Adv Radiat Biol. 9:143–198. 1981. View Article : Google Scholar | |
Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998. View Article : Google Scholar : PubMed/NCBI | |
Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S and Pommier Y: GammaH2AX and cancer. Nat Rev Cancer. 8:957–967. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bourton EC, Plowman PN, Smith D, Arlett CF and Parris CN: Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radio-therapy treatment. Int J Cancer. 129:2928–2934. 2011. View Article : Google Scholar : PubMed/NCBI | |
Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, et al: Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther. 1:295–302. 2002.PubMed/NCBI | |
Peña LA, Fuks Z and Kolesnick RN: Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res. 60:321–327. 2000.PubMed/NCBI | |
Kumar P, Miller AI and Polverini PJ: p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem. 279:43352–43360. 2004. View Article : Google Scholar : PubMed/NCBI | |
Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927. 1999. View Article : Google Scholar : PubMed/NCBI | |
Dangi S, Cha H and Shapiro P: Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cell Signal. 15:667–675. 2003. View Article : Google Scholar : PubMed/NCBI | |
Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N: Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 22:7831–7841. 2002. View Article : Google Scholar : PubMed/NCBI | |
Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 351:95–105. 2000. View Article : Google Scholar : PubMed/NCBI | |
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI | |
Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI | |
Figueroa C, Tarras S, Taylor J and Vojtek AB: Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex. J Biol Chem. 278:47922–47927. 2003. View Article : Google Scholar : PubMed/NCBI | |
Shonai T, Adachi M, Sakata K, Takekawa M, Endo T, Imai K and Hareyama M: MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ. 9:963–971. 2002. View Article : Google Scholar : PubMed/NCBI |